Ketanserin and captopril interaction in the treatment of essential hypertensives
- PMID: 2285641
- DOI: 10.1007/BF00053442
Ketanserin and captopril interaction in the treatment of essential hypertensives
Abstract
The aim of the study was to evaluate whether the combination of ketanserin with captopril exerts an additive antihypertensive effect, as compared with single drug treatment. Twelve patients with uncomplicated moderate essential hypertension received, according to a randomized, double-blind, crossover design, ketanserin (40 mg twice daily), captopril (50 mg twice daily), the combination of the two drugs at these dosages, and the corresponding placebo, each treatment being given for 1 month. Both ketanserin and captopril as monotherapy similarly and significantly reduced blood pressure as compared with placebo (p less than 0.001). The combination treatment of ketanserin plus captopril further and significantly reduced blood pressure when compared with single drug treatment (p less than 0.001). Moreover, the percentage of responders and patients whose blood pressure was normalized were significantly greater under the combined treatment than under ketanserin or captopril monotherapy (p less than 0.001). These data indicate that the combination of ketanserin plus captopril exerts a clear additive antihypertensive effect when compared with each treatment as monotherapy, a finding that suggests this combination can be usefully employed in the treatment of hypertensive patients.
Similar articles
-
Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study.J Hypertens Suppl. 1987 Dec;5(4):S139-42. doi: 10.1097/00004872-198712004-00023. J Hypertens Suppl. 1987. PMID: 3326920 Clinical Trial.
-
Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.J Cardiovasc Pharmacol. 1985;7 Suppl 7:S164-7. doi: 10.1097/00005344-198500077-00046. J Cardiovasc Pharmacol. 1985. PMID: 2412043 Clinical Trial.
-
Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study.J Hypertens Suppl. 1987 Dec;5(5):S599-602. J Hypertens Suppl. 1987. PMID: 3327931 Clinical Trial.
-
Serotonergic blockade compared with beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin with propranolol.J Clin Pharmacol. 1988 Nov;28(11):1008-16. doi: 10.1002/j.1552-4604.1988.tb03122.x. J Clin Pharmacol. 1988. PMID: 2907519 Clinical Trial.
-
Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.Coron Artery Dis. 1994 Oct;5(10):829-44. Coron Artery Dis. 1994. PMID: 7866603 Review.
Cited by
-
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843651 Free PMC article.
-
Role of ACE inhibitors in uncomplicated essential hypertension.Br Heart J. 1994 Sep;72(3 Suppl):S15-23. doi: 10.1136/hrt.72.3_suppl.s15. Br Heart J. 1994. PMID: 7946798 Free PMC article. Review. No abstract available.
-
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010. Drugs. 1990. PMID: 2079001 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical